Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

57
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
57
Hypersensitivity Reactions: Cytolytic Reactions01:01

Hypersensitivity Reactions: Cytolytic Reactions

65
Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...
65
Acute Kidney Injury II: Pathophysiology01:29

Acute Kidney Injury II: Pathophysiology

1.3K
Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
1.3K
Complement System01:27

Complement System

11.3K
The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a...
11.3K
Complementation Tests00:49

Complementation Tests

6.3K
A complementation test is a simple cross to identify whether the two mutations are located on the same gene or different genes. It was first performed by Edward Lewis in the 1940s while working on fruit flies. He developed the test to identify the location and arrangement of different mutations on chromosomes.
Organisms heterozygous for different mutations are crossed pairwise in all combinations. If present on different genes, the mutations can complement each other by providing the missing...
6.3K
Humoral Immune Responses01:36

Humoral Immune Responses

84.6K
Overview
84.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Properdin deficiency or anti-properdin treatment ameliorates disease in the C3 gain-of-function mouse model of atypical haemolytic uraemic syndrome.

Frontiers in immunology·2026
Same author

C3 Glomerulonephritis Associated With Anti-complement Factor B Antibodies Following Anti-cancer Treatment With Pembrolizumab.

Kidney medicine·2026
Same author

Complement biomarkers during iptacopan treatment - Authors' reply.

Lancet (London, England)·2026
Same author

Clinical and cost-effectiveness of eculizumab withdrawal in atypical haemolytic uraemic syndrome: the SETS aHUS multi-centre, open-label, prospective and single-arm study.

Health technology assessment (Winchester, England)·2026
Same author

Eculizumab withdrawal and monitoring in atypical haemolytic uraemic syndrome (SETS aHUS): a multicentre, open label, prospective, single arm trial.

The Lancet regional health. Europe·2026
Same author

Current and Emerging Therapies for C3 Glomerulopathy and Primary (Idiopathic) Immune Complex Membranoproliferative Glomerulonephritis.

Kidney international reports·2026
Same journal

Correlation between urinary soluble CD163 and endocapillary proliferation and fibrinoid necrosis in IgA vasculitis with nephritis.

Pediatric nephrology (Berlin, Germany)·2026
Same journal

SGLT2i, anti-endothelin A and double endothelin and angiotensin inhibitors: a new future for chronic kidney disease in children.

Pediatric nephrology (Berlin, Germany)·2026
Same journal

The role of urinary trehalase levels in the early diagnosis of acute kidney injury in dehydrated children.

Pediatric nephrology (Berlin, Germany)·2026
Same journal

Neuron-specific enolase and brain-derived neurotrophic factor as developmental neurovascular markers in chronic kidney disease and kidney transplantation.

Pediatric nephrology (Berlin, Germany)·2026
Same journal

Chronic hyponatraemia with a reset osmostat: when abnormal is normal.

Pediatric nephrology (Berlin, Germany)·2026
Same journal

Clinical value of repeat kidney biopsy in pediatric IgA vasculitis nephritis.

Pediatric nephrology (Berlin, Germany)·2026
See all related articles

Related Experiment Video

Updated: Feb 27, 2026

A Novel Strategy Combining Array-CGH, Whole-exome Sequencing and In Utero Electroporation in Rodents to Identify Causative Genes for Brain Malformations
08:22

A Novel Strategy Combining Array-CGH, Whole-exome Sequencing and In Utero Electroporation in Rodents to Identify Causative Genes for Brain Malformations

Published on: December 1, 2017

9.2K

Genetics and complement in atypical HUS.

David Kavanagh1, Tim Goodship

  • 1The Institute of Human Genetics, Newcastle University, Newcastle upon Tyne, UK. david.kavanagh@ncl.ac.uk

Pediatric Nephrology (Berlin, Germany)
|June 8, 2010
PubMed
Summary
This summary is machine-generated.

Genetic factors drive atypical hemolytic uremic syndrome (aHUS) by over-activating the complement system. Mutations in complement proteins and autoantibodies impair regulation, leading to this serious condition.

More Related Videos

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

12.3K
A Strategy to Identify de Novo Mutations in Common Disorders such as Autism and Schizophrenia
05:51

A Strategy to Identify de Novo Mutations in Common Disorders such as Autism and Schizophrenia

Published on: June 15, 2011

26.5K

Related Experiment Videos

Last Updated: Feb 27, 2026

A Novel Strategy Combining Array-CGH, Whole-exome Sequencing and In Utero Electroporation in Rodents to Identify Causative Genes for Brain Malformations
08:22

A Novel Strategy Combining Array-CGH, Whole-exome Sequencing and In Utero Electroporation in Rodents to Identify Causative Genes for Brain Malformations

Published on: December 1, 2017

9.2K
High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

12.3K
A Strategy to Identify de Novo Mutations in Common Disorders such as Autism and Schizophrenia
05:51

A Strategy to Identify de Novo Mutations in Common Disorders such as Autism and Schizophrenia

Published on: June 15, 2011

26.5K

Area of Science:

  • Immunology
  • Genetics
  • Nephrology

Background:

  • Atypical hemolytic uremic syndrome (aHUS) is characterized by complement over-activation.
  • Genetic defects in complement regulatory proteins are key to aHUS pathogenesis.
  • Mutations in factor H, factor I, and other regulators have been identified.

Purpose of the Study:

  • To review the genetic causes of aHUS.
  • To discuss the functional consequences of these genetic alterations.
  • To explore the clinical impact of genetic factors in aHUS.

Main Methods:

  • Literature review of genetic causes of aHUS.
  • Analysis of functional consequences of identified mutations.
  • Correlation of genetic findings with clinical manifestations.

Main Results:

  • Mutations in complement regulatory proteins (factor H, I, MCP, thrombomodulin) decrease regulation.
  • Autoantibodies against factor H also impair complement control.
  • Gain-of-function mutations in C3 and factor B contribute to aHUS.

Conclusions:

  • Genetic factors are central to aHUS pathogenesis.
  • Understanding these genetic underpinnings is crucial for diagnosis and management.
  • Further research into genetic causes will improve clinical outcomes for aHUS patients.